{"studies":[{"key":"episode-2026","label":"Mertens et al. · EPISODE · 2026","doi":"10.1001/jamapsychiatry.2026.0132","pmid":"41848690","nct":"NCT04670081","population":"Treatment-resistant depression; two German centers","design":"Phase 2b randomized trial; 25 mg, 5 mg and nicotinamide comparisons with psychotherapy","sample":"144 randomized; 142 in the primary efficacy analysis","endpoint":"HAMD17 response at week 6, before the second administration","result":"Primary comparison not significant: response 17.0% with 25 mg versus 10.6% with nicotinamide; adjusted odds ratio 1.73 (95% CI 0.53–6.23), p=0.19.","limitation":"The first hierarchical test failed; secondary symptom changes are exploratory. Two serious adverse reactions followed 25 mg, including one case of hallucinogen persisting perception disorder.","outcome":"Primary endpoint not met","paper":{"id":133,"title":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","authors":"Mertens Lea J., Koslowski Michael, Betzler Felix, Brand Manuela, Evens Ricarda, Kärtner Laura, Jungaberle Andrea, Jungaberle Henrik, Majić Tomislav, Schmitz Christian N., Ströhle Andreas, Scharf Dennis, Spangemacher Moritz, Wolff Max, Assadi Zahra, Bahri Scharif, Becher Lilith, Färber Luca V., Kirchen Niklas, Kulakova Eugenia, Kunz Linda, Meijer Andy, Rohrmoser Barbara, Wellek Stefan, Berger Moritz M., Gründer Gerhard","journal":"JAMA Psychiatry","publication_date":"2026-05-01","publication_year":2026,"doi":"10.1001/jamapsychiatry.2026.0132","pubmed_id":"41848690","openalex_id":"https://openalex.org/W7138853109","source_url":"https://doi.org/10.1001/jamapsychiatry.2026.0132","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-06-30 22:38:07","last_checked":"2026-08-09 08:28:48","bibtex":null,"source_record_id":"PMID:41848690","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1001/jamapsychiatry.2026.0132","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"PMID:41848690","source_url":"https://doi.org/10.1001/jamapsychiatry.2026.0132","doi":"10.1001/jamapsychiatry.2026.0132","pmid":"41848690","publication_date":"2026-05-01","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1001/jamapsychiatry.2026.0132","topic":"depression","source_checked":"2026-10-07"},{"key":"rucker-2026","label":"Rucker et al. · NHS feasibility trial · 2026","doi":"10.1038/s41591-026-04541-0","pmid":"42562964","nct":null,"population":"Treatment-resistant major depression; one NHS site in England","design":"Randomized, double-blind feasibility trial; psilocybin versus placebo with psychological support","sample":"60 randomized; 59 completed MADRS at all follow-up visits","endpoint":"Primary outcomes: recruitment, retention and estimation of MADRS variance","result":"Week-3 adjusted MADRS difference −10.41 points (95% CI −14.86 to −5.95), favoring psilocybin; the report describes persistence at week 6.","limitation":"An encouraging symptom estimate from a feasibility study is not a confirmatory efficacy endpoint. A single site and six-week follow-up limit generalization.","outcome":"Feasibility study","paper":{"id":5778,"title":"Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.","authors":"Rucker JJ, Mantingh T, Kerr-Gaffney J, Bird C, Chu P, Modlin NL, Campbell-Coker K, Hambleton S, Seath P, Hignett R, Fennema D, Hampsey E, Tsapekos D, Thomas RJ, Cattell J, Jafari H, Day C, Borissova A, Lloyd M, Boardman-Pretty T, Seynaeve M, Askari F, Creed M, Baxter L, Rifkin-Zybutz R, Butler M, Jelen LA, Carter B, Young AH.","journal":"Nature medicine","publication_date":"2026-08-06","publication_year":2026,"doi":"10.1038/s41591-026-04541-0","pubmed_id":"42562964","openalex_id":"https://openalex.org/W7196979420","source_url":"https://doi.org/10.1038/s41591-026-04541-0","substance_tags":"psilocybin","topic_tags":"Depression,Randomized Controlled Trial,Treatment-Resistant Depression,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-07 01:20:12","last_checked":"2026-08-13 01:20:27","bibtex":null,"source_record_id":"PMID:42562964","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41591-026-04541-0","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42562964","source_url":"https://doi.org/10.1038/s41591-026-04541-0","doi":"10.1038/s41591-026-04541-0","pmid":"42562964","publication_date":"2026-08-06","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1038/s41591-026-04541-0","topic":"depression","source_checked":"2026-10-07"},{"key":"yngwe-2026","label":"Yngwe et al. · Stockholm trial · 2026","doi":"10.1001/jamanetworkopen.2026.12589","pmid":"42138922","nct":"NCT04630964","population":"Moderate to severe recurrent major depressive disorder","design":"Randomized, double-blind trial; psilocybin versus niacin with five support sessions","sample":"35 randomized: 17 psilocybin, 18 niacin","endpoint":"Change in clinician-rated MADRS at day 8; follow-up through day 365","result":"Day-8 difference −7.27 points (95% CI −12.89 to −1.65), p=0.01. The clinician-rated difference was not significant at day 365: −3.68 (95% CI −9.30 to 1.94), p=0.20.","limitation":"A small sample; later self-reported outcomes are secondary and differ from the clinician-rated endpoint. Two psilocybin participants reported persistent severe anxiety requiring medical attention.","outcome":"Primary endpoint met","paper":{"id":123,"title":"Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression","authors":"Yngwe Hampus, Plavén-Sigray Pontus, Ekman Carl Johan, Henje Eva, Berglund Anders, Tiger Mikael, Beckman Maria, Lundberg Johan","journal":"JAMA Network Open","publication_date":"2026-05-15","publication_year":2026,"doi":"10.1001/jamanetworkopen.2026.12589","pubmed_id":"42138922","openalex_id":"https://openalex.org/W7161294763","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.12589","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Clinical Trial,Adverse Events","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-06-30 22:38:07","last_checked":"2026-08-09 08:28:47","bibtex":null,"source_record_id":"PMID:42138922","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1001/jamanetworkopen.2026.12589","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"PMID:42138922","source_url":"https://doi.org/10.1001/jamanetworkopen.2026.12589","doi":"10.1001/jamanetworkopen.2026.12589","pmid":"42138922","publication_date":"2026-05-15","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1001/jamanetworkopen.2026.12589","topic":"depression","source_checked":"2026-10-07"},{"key":"raison-2023","label":"Raison et al. · 2023","doi":"10.1001/jama.2023.14530","pmid":"37651119","nct":"NCT03866174","population":"Major depressive disorder; 11 US research sites","design":"Phase 2 randomized trial; psilocybin versus niacin with psychological support","sample":"104 randomized: 51 psilocybin, 53 niacin","endpoint":"Change in centrally rated MADRS from baseline to day 43","result":"Between-group difference −12.3 points (95% CI −17.5 to −7.2), p<0.001, favoring psilocybin.","limitation":"Six-week follow-up and selected eligibility. Participants using psychotropic medication could enter following taper. No serious treatment-emergent adverse events were reported, but overall and severe adverse events were more frequent with psilocybin.","outcome":"Primary endpoint met","paper":{"id":1379,"title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.","authors":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR","journal":"JAMA","publication_date":"2023-09-05","publication_year":2023,"doi":"10.1001/jama.2023.14530","pubmed_id":"37651119","openalex_id":"https://openalex.org/W4386305655","source_url":"https://pubmed.ncbi.nlm.nih.gov/37651119/","substance_tags":"psilocybin","topic_tags":"Depression,Addiction,Clinical Trial,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:12","bibtex":null,"source_record_id":"PMID:37651119","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37651119/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37651119","source_url":"https://pubmed.ncbi.nlm.nih.gov/37651119/","doi":"10.1001/jama.2023.14530","pmid":"37651119","publication_date":"2023-09-05","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1001/jama.2023.14530","topic":"depression","source_checked":"2026-10-07"},{"key":"von-rotz-2023","label":"von Rotz et al. · 2023","doi":"10.1016/j.eclinm.2022.101809","pmid":"36636296","nct":"NCT03715127","population":"Major depressive disorder; Zürich, Switzerland","design":"Randomized, double-blind trial; psilocybin versus placebo with psychological support","sample":"52 participants; 26 per group","endpoint":"Change in MADRS and Beck Depression Inventory at day 14","result":"Greater symptom reduction with psilocybin; reported MADRS between-group effect size d=0.97, p=0.0011.","limitation":"The primary assessment was only two weeks after treatment. The selected sample and single-center design do not establish long-term effectiveness in routine care.","outcome":"Primary outcomes favored psilocybin","paper":{"id":1567,"title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.","authors":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX","journal":"EClinicalMedicine","publication_date":"2023-02-01","publication_year":2023,"doi":"10.1016/j.eclinm.2022.101809","pubmed_id":"36636296","openalex_id":"https://openalex.org/W4313530670","source_url":"https://pubmed.ncbi.nlm.nih.gov/36636296/","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Randomized Controlled Trial,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:17","bibtex":null,"source_record_id":"PMID:36636296","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36636296/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36636296","source_url":"https://pubmed.ncbi.nlm.nih.gov/36636296/","doi":"10.1016/j.eclinm.2022.101809","pmid":"36636296","publication_date":"2023-02-01","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1016/j.eclinm.2022.101809","topic":"depression","source_checked":"2026-10-07"},{"key":"goodwin-2022","label":"Goodwin et al. · COMP001 · 2022","doi":"10.1056/NEJMoa2206443","pmid":"36322843","nct":"NCT03775200","population":"Treatment-resistant depression","design":"Phase 2 randomized, double-blind trial; 25 mg and 10 mg compared with 1 mg, with psychological support","sample":"233: 79 in the 25 mg group, 75 in the 10 mg group, 79 in the 1 mg group","endpoint":"Change in MADRS at week 3; sustained response assessed through week 12","result":"25 mg versus 1 mg: −6.6 MADRS points (95% CI −10.2 to −2.9), p<0.001. The 10 mg comparison was not significant.","limitation":"Sustained response at week 12 did not support the short-term result. Adverse events occurred in 77%; suicidal ideation, behavior or self-injury occurred across dose groups. This does not establish their cause.","outcome":"25 mg primary comparison significant","paper":{"id":1642,"title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.","authors":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E","journal":"The New England journal of medicine","publication_date":"2022-11-03","publication_year":2022,"doi":"10.1056/nejmoa2206443","pubmed_id":"36322843","openalex_id":"https://openalex.org/W4308146982","source_url":"https://pubmed.ncbi.nlm.nih.gov/36322843/","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Treatment-Resistant Depression,Safety","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:18","bibtex":null,"source_record_id":"PMID:36322843","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36322843/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36322843","source_url":"https://pubmed.ncbi.nlm.nih.gov/36322843/","doi":"10.1056/nejmoa2206443","pmid":"36322843","publication_date":"2022-11-03","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1056/nejmoa2206443","topic":"depression","source_checked":"2026-10-07"},{"key":"carhart-harris-2021","label":"Carhart-Harris et al. · 2021","doi":"10.1056/NEJMoa2032994","pmid":"33852780","nct":"NCT03429075","population":"Long-standing, moderate to severe major depressive disorder","design":"Phase 2 randomized trial; psilocybin treatment versus daily escitalopram, with psychological support in both groups","sample":"59: 30 assigned psilocybin, 29 escitalopram","endpoint":"Change in self-rated QIDS-SR-16 at week 6","result":"Primary between-group difference −2.0 points (95% CI −5.0 to 0.9), p=0.17; no statistically significant difference.","limitation":"Several secondary outcomes favored psilocybin without correction for multiple comparisons. The primary result establishes neither superiority nor equivalence to escitalopram.","outcome":"Primary endpoint not met","paper":{"id":2165,"title":"Trial of Psilocybin versus Escitalopram for Depression.","authors":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ","journal":"The New England journal of medicine","publication_date":"2021-04-15","publication_year":2021,"doi":"10.1056/nejmoa2032994","pubmed_id":"33852780","openalex_id":"https://openalex.org/W3156937150","source_url":"https://pubmed.ncbi.nlm.nih.gov/33852780/","substance_tags":"psilocybin","topic_tags":"Depression,Receptor Pharmacology,Clinical Trial,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:22","bibtex":null,"source_record_id":"PMID:33852780","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/33852780/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:33852780","source_url":"https://pubmed.ncbi.nlm.nih.gov/33852780/","doi":"10.1056/nejmoa2032994","pmid":"33852780","publication_date":"2021-04-15","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1056/nejmoa2032994","topic":"depression","source_checked":"2026-10-07"},{"key":"davis-2021","label":"Davis et al. · 2021","doi":"10.1001/jamapsychiatry.2020.3285","pmid":"33146667","nct":"NCT03181529","population":"Major depressive disorder; participants not taking antidepressants","design":"Randomized immediate-treatment versus waiting-list trial with supportive psychotherapy","sample":"27 randomized; 24 completed treatment and post-session assessments","endpoint":"GRID-HAMD depression ratings at one and four weeks after the intervention","result":"Depression ratings were lower in the immediate-treatment group than in the waiting-list group at the corresponding assessments.","limitation":"A small evaluable sample and a waiting-list comparator. The design does not separate drug effects from expectancy, therapist contact and the treatment setting.","outcome":"Positive waiting-list comparison","paper":{"id":2160,"title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.","authors":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR","journal":"JAMA psychiatry","publication_date":"2021-05-01","publication_year":2021,"doi":"10.1001/jamapsychiatry.2020.3285","pubmed_id":"33146667","openalex_id":"https://openalex.org/W3096208965","source_url":"https://pubmed.ncbi.nlm.nih.gov/33146667/","substance_tags":"psilocybin","topic_tags":"Depression,Consciousness,Clinical Trial,Treatment-Resistant Depression","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:22","bibtex":null,"source_record_id":"PMID:33146667","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/33146667/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:33146667","source_url":"https://pubmed.ncbi.nlm.nih.gov/33146667/","doi":"10.1001/jamapsychiatry.2020.3285","pmid":"33146667","publication_date":"2021-05-01","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1001/jamapsychiatry.2020.3285","topic":"depression","source_checked":"2026-10-07"},{"key":"relapse-2025","label":"Swiss relapse-prevention trial · 2025","doi":"10.1016/j.eclinm.2025.103149","pmid":"40144690","nct":"NCT04141501","population":"Alcohol use disorder following recent withdrawal treatment","design":"Randomized placebo-controlled trial; one supervised session with brief psychotherapy","sample":"37 participants in the four-week analysis: 18 psilocybin, 19 placebo","endpoint":"Abstinence and average alcohol consumption at four weeks","result":"Neither primary comparison was significant: abstinence p=0.55; alcohol use p=0.51. Six-month comparisons also showed no significant group difference.","limitation":"Small sample; a different population, dosing schedule and psychotherapy programme from the 2022 trial. The result does not establish equivalence or rule out a clinically relevant effect.","outcome":"Primary comparisons inconclusive","paper":null,"work_id":"https://doi.org/10.1016/j.eclinm.2025.103149","topic":"alcohol-use-disorder","source_checked":"2026-10-07"},{"key":"bogenschutz-2022","label":"Bogenschutz et al. · 2022","doi":"10.1001/jamapsychiatry.2022.2096","pmid":"36001306","nct":"NCT02061293","population":"Adults with alcohol dependence; two US academic centres","design":"Randomized trial; two psilocybin or diphenhydramine sessions alongside 12 weeks of psychotherapy","sample":"95 randomized; 93 received study medication and entered the primary analysis","endpoint":"Percentage of heavy drinking days across 32 weeks after the first session","result":"9.7% with psilocybin versus 23.6% with active placebo: 13.9 percentage points fewer heavy drinking days (95% CI 3.0–24.7), p=0.01.","limitation":"Participants could often identify their allocation. Results concern the combined supervised intervention and selected participants, not psilocybin alone or every person with alcohol use disorder.","outcome":"Primary endpoint favored psilocybin","paper":{"id":1681,"title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.","authors":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L","journal":"JAMA psychiatry","publication_date":"2022-10-01","publication_year":2022,"doi":"10.1001/jamapsychiatry.2022.2096","pubmed_id":"36001306","openalex_id":"https://openalex.org/W4292937262","source_url":"https://pubmed.ncbi.nlm.nih.gov/36001306/","substance_tags":"psilocybin","topic_tags":"Addiction,Clinical Trial,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:19","bibtex":null,"source_record_id":"PMID:36001306","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36001306/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36001306","source_url":"https://pubmed.ncbi.nlm.nih.gov/36001306/","doi":"10.1001/jamapsychiatry.2022.2096","pmid":"36001306","publication_date":"2022-10-01","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1001/jamapsychiatry.2022.2096","topic":"alcohol-use-disorder","source_checked":"2026-10-07"},{"key":"pilot-2015","label":"Bogenschutz et al. · 2015 pilot","doi":"10.1177/0269881114565144","pmid":"25586396","nct":null,"population":"Ten volunteers with alcohol dependence","design":"Single-group proof-of-concept study; supervised sessions with motivational and preparatory therapy","sample":"10 volunteers; no randomized comparison group","endpoint":"Drinking and abstinence over treatment and follow-up","result":"The investigators observed increased abstinence after dosing, with gains broadly maintained through 36 weeks.","limitation":"Without a concurrent control, improvement cannot be attributed specifically to psilocybin. This preliminary report supported further trials rather than confirming efficacy.","outcome":"Preliminary uncontrolled finding","paper":{"id":2545,"title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.","authors":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2015-03-01","publication_year":2015,"doi":"10.1177/0269881114565144","pubmed_id":"25586396","openalex_id":"https://openalex.org/W2075238613","source_url":"https://pubmed.ncbi.nlm.nih.gov/25586396/","substance_tags":"psilocybin","topic_tags":"Addiction,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:27","bibtex":null,"source_record_id":"PMID:25586396","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/25586396/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:25586396","source_url":"https://pubmed.ncbi.nlm.nih.gov/25586396/","doi":"10.1177/0269881114565144","pmid":"25586396","publication_date":"2015-03-01","importer_version":"2.1.3","text_redistributed":false}},"work_id":"https://doi.org/10.1177/0269881114565144","topic":"alcohol-use-disorder","source_checked":"2026-10-07"}]}